SV

Street Verdict

Analyst Scorecard

AJANTPHARM · NSE

Ajanta Pharma Limited

₹3,317.7

+1.45% (+₹47.4)

Prev. close

₹3,270.3

Volume

84,184

Delivery %

57.7%

As of

20 Nov 2026

Price history

₹3,317.7-₹388.7 (-10.49%) · 3M
18 Aug 2026 → 20 Nov 2026
3,3003,4003,5003,6003,70018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 5 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Ajanta Pharma Limited

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Yogesh Mannalal Agrawal M.B.A

Headquarters

Mumbai

Employees

10,421

Key stats

Market cap

₹41,445.16 Cr

P/E ratio (TTM)

32.8

Dividend yield

1.93%

EPS (TTM)

₹101.01

Beta (1Y · daily vs NIFTY 50)

0.47

Beta (5Y · monthly vs NIFTY 50)

0.72

Shares float

4.20 Cr

EPS · quarter ended Sept 2026

₹31.03

Financial Performance

01 · Financials

0 Cr2000 Cr4000 Cr6000 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0255075100₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

010203040₹-500%0%500%1000%12 Nov 2009 Nov 2111 Nov 2204 Aug 2308 Feb 2406 Nov 2410 Nov 2505 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr2500 Cr5000 Cr7500 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr2500 Cr5000 Cr7500 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr250 Cr500 Cr750 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

Total assets for FY23, FY24, FY25 and FY26: the figure the company printed, which its own totals confirm and the series' figure did not.

08 · Profit & Loss — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,915.67 Cr₹3,456.67 Cr₹3,841.28 Cr₹4,293.31 Cr₹4,742.60 Cr₹5,624.93 Cr
₹2,015.49 Cr₹2,547.19 Cr₹3,096.03 Cr₹3,179.38 Cr₹3,553.44 Cr₹4,247.28 Cr
Profit before tax
₹900.18 Cr₹909.48 Cr₹745.25 Cr₹1,113.93 Cr₹1,189.16 Cr₹1,377.65 Cr
₹246.31 Cr₹196.79 Cr₹157.27 Cr₹297.76 Cr₹268.77 Cr₹321.65 Cr
₹647.42 Cr₹704.71 Cr₹602.83 Cr₹816.98 Cr₹922.24 Cr₹1,085.08 Cr
Profit for the year
₹653.87 Cr₹712.68 Cr₹587.98 Cr₹816.17 Cr₹920.39 Cr₹1,056.00 Cr
₹-6.45 Cr₹-7.97 Cr₹14.85 Cr₹81.00 L₹1.85 Cr₹29.08 Cr
Basic (*)
75.0954.9745.8964.8273.5684.53
Diluted (₹)
75.0954.9645.8964.7773.5384.51

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

09 · Balance Sheet — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,751.13 Cr₹1,791.12 Cr₹1,845.02 Cr₹1,907.47 Cr₹2,171.92 Cr₹2,419.41 Cr
(a) Inventories
₹766.47 Cr₹791.07 Cr₹815.63 Cr₹828.36 Cr₹903.85 Cr₹938.54 Cr
(i) Investments
₹175.67 Cr₹121.86 Cr₹510.27 Cr₹330.05 Cr₹438.71 Cr₹559.85 Cr
(ii) Trade receivables
₹738.43 Cr₹1,019.81 Cr₹1,056.90 Cr₹1,246.84 Cr₹1,182.74 Cr₹1,853.88 Cr
(iii) Cash and cash equivalents
₹177.51 Cr₹206.36 Cr₹329.83 Cr₹129.49 Cr₹175.12 Cr₹103.26 Cr
(iv) Bank balances other than cash and cash equivalents
₹32.10 Cr₹5.43 Cr₹1.07 Cr₹1.28 Cr₹1.12 Cr₹1.51 Cr
(v) Loans
₹8.03 Cr₹6.37 Cr₹17.39 Cr₹33.96 Cr₹2.54 Cr₹1.68 Cr
Other financial assets
₹5.86 Cr₹17.69 Cr————
(vi) Other financial assets
₹16.37 Cr₹12.04 Cr₹2.48 Cr₹19.02 Cr₹2.32 Cr₹8.98 Cr
(c) Other current assets
₹123.52 Cr₹95.87 Cr₹91.61 Cr₹133.07 Cr₹123.30 Cr₹267.73 Cr
——₹2,834.00 Cr—₹2,843.03 Cr₹3,735.43 Cr
Total current assets
₹2,027.59 Cr₹2,264.46 Cr₹2,825.18 Cr₹2,730.92 Cr₹2,829.70 Cr₹3,735.43 Cr
(d) Assets classified as held for sale
——₹8.82 Cr₹8.85 Cr₹13.33 Cr—
Total assets
₹3,778.72 Cr₹4,055.58 Cr₹4,679.02 Cr₹4,638.39 Cr₹5,014.95 Cr₹6,154.84 Cr
₹2,995.63 Cr₹3,264.34 Cr₹3,387.99 Cr₹3,567.36 Cr₹3,790.29 Cr₹4,527.09 Cr
Other Liabilities
₹3.34 Cr₹3.00 Cr————
(i) Lease liabilities
₹18.17 Cr₹16.93 Cr₹24.95 Cr₹23.52 Cr₹34.72 Cr₹39.42 Cr
(ii) Other financial liabilities
₹1.25 Cr₹1.09 Cr₹1.01 Cr₹1.37 Cr₹1.05 Cr₹1.82 Cr
(b) Other non current liabilities
——₹2.67 Cr₹2.34 Cr₹2.00 Cr₹1.67 Cr
(c) Provisions
₹17.93 Cr₹19.32 Cr₹24.15 Cr₹39.54 Cr₹80.27 Cr₹51.15 Cr
(d) Deferred tax liabilities (net)
₹92.17 Cr₹101.87 Cr₹97.72 Cr₹108.50 Cr₹110.52 Cr₹117.94 Cr
Total non-current liabilities
₹134.46 Cr₹143.85 Cr₹151.75 Cr₹175.27 Cr₹228.56 Cr₹212.00 Cr
Borrowings
₹9.00 L₹27.00 L₹18.00 L———
(i) Borrowings
₹1.60 Cr₹1.64 Cr₹1.25 Cr₹1.49 Cr₹2.59 Cr₹211.99 Cr
(ii) Lease liabilities
₹11.50 Cr₹6.19 Cr₹9.25 Cr₹10.27 Cr₹10.11 Cr₹8.76 Cr
Other liabilities
₹30.42 Cr₹64.42 Cr————
(a) total outstanding dues of micro and small enterprises; and
₹24.48 Cr₹27.98 Cr₹37.94 Cr₹20.64 Cr₹21.55 Cr₹54.17 Cr
(b) total outstanding dues of creditors other than micro and small enterprises.
₹349.38 Cr₹299.19 Cr₹384.83 Cr₹442.56 Cr₹432.65 Cr₹490.13 Cr
(iv) Other financial liabilities
₹172.13 Cr₹230.59 Cr₹636.84 Cr₹298.03 Cr₹374.20 Cr₹495.82 Cr
(b) Other current liabilities
——₹23.15 Cr₹59.73 Cr₹91.12 Cr₹119.00 Cr
(c) Provisions
₹11.71 Cr₹10.81 Cr₹14.02 Cr₹17.76 Cr₹23.35 Cr₹30.39 Cr
(d) Income tax liabilities (net)
₹48.92 Cr₹7.94 Cr₹33.07 Cr₹44.77 Cr₹40.53 Cr₹5.49 Cr
——₹1,139.28 Cr———
Total current liabilities
₹648.63 Cr₹647.39 Cr₹1,139.28 Cr₹895.76 Cr₹996.10 Cr₹1,415.75 Cr
Total liabilities
₹783.09 Cr†₹791.24 Cr₹1,291.03 Cr₹1,071.03 Cr₹1,224.66 Cr₹1,627.74 Cr
Total Equity and Liabilities
₹3,778.72 Cr₹4,055.58 Cr₹4,679.02 Cr₹4,638.39 Cr₹5,014.95 Cr₹6,154.84 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

All years: consolidated statements.

10 · Cash Flow Statement — as filed

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹576.31 Cr₹561.71 Cr₹792.11 Cr₹785.07 Cr₹1,157.23 Cr₹529.19 Cr
₹-282.38 Cr₹-74.10 Cr₹-559.60 Cr₹65.39 Cr₹-376.52 Cr₹-428.92 Cr
₹-24.36 Cr₹27.90 Cr₹124.31 Cr₹-200.60 Cr₹47.30 Cr₹-67.65 Cr
Cash and cash equivalents as at the beginning of the year
₹202.35 Cr₹177.51 Cr₹206.36 Cr₹329.83 Cr₹129.49 Cr₹175.12 Cr
Cash and cash equivalents as at the end of the year
₹177.99 Cr₹205.41 Cr₹330.67 Cr₹129.23 Cr₹176.79 Cr₹107.47 Cr
₹177.51 Cr₹206.36 Cr₹329.83 Cr₹129.49 Cr₹175.12 Cr₹103.26 Cr

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: consolidated statements.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Dec 21(2Q)Mar 22–Sep 22(3Q)Dec 22–Mar 23(2Q)Apr 23–Mar 24(5Q)Jun 24Sep 24–Jun 25(4Q)Sep 25–Mar 26(3Q)Jun 26
Promoter70.34%70.48%66.11%66.21%66.27%66.26%66.25%63.48%
Public29.66%29.52%33.89%33.79%33.73%33.74%33.75%36.52%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Ajanta Pharma Limited₹41,482.65 Cr₹3,316.732.99.1623.3%0.06+17.9%+27.0%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

AJANTPHARM

Ajanta Pharma Q2 FY27 Earnings Call Transcript Now Available

Ajanta Pharma Limited has made the transcript of its Q2 FY27 earnings call publicly available on its investor relations website. The call, held on October 30, 2026, discussed the company's financial performance for the July to September 2026 quarter. This disclosure fulfills regulatory obligations and provides investors access to management commentary.

AJANTPHARM

Pharma sector stocks today, November 3: J.B. Chemicals falls 3.87%, Biocon down 2.76%, Ajanta Pharma declines 1.58%

Business Upturn · 19 days ago